Muhammad Akram

Muhammad Akram

Legend Biotech - / United States
Others
AD Scientific Index ID: 4970695
person_outline Muhammad Akram's MOST POPULAR ARTICLES
1-) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1 … JG Berdeja, D Madduri, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ... The Lancet 398 (10297), 314-324, 2021 3542021
2-) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studiesAD Cohen, S Parekh, BD Santomasso, J Gállego Pérez-Larraya, ...Blood cancer journal 12 (2), 32, 20221512022
3-) CARTITUDE-1: phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myelomaD Madduri, JG Berdeja, SZ Usmani, A Jakubowiak, M Agha, AD Cohen, ...Blood 136, 22-25, 20201372020
4-) Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agentsAD Cohen, MV Mateos, YC Cohen, P Rodriguez-Otero, B Paiva, ...Blood, 20221342022
5-) Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM …SZ Usmani, JG Berdeja, D Madduri, AJ Jakubowiak, ME Agha, AD Cohen, ...Journal of Clinical Oncology 39 (15_suppl), 8005-8005, 2021452021